Yesterday, M1 Kliniken AG successfully held its Annual General Meeting 2020. In his presentation, the Management Board gave an outline of the company's prosperous development in the 2019 financial year, which was accompanied by a significant …
M1 Kliniken AG acquires about 48 % of the share capital of HAEMATO AG from MPH Health Care AG. Transfer of the HAEMATO shares within the framework of a capital increase through contribution in kind Focus of both companies on their respective core …
M1 Kliniken AG today published its consolidated financial statements for 2019. The M1 Group has increased its consolidated revenue by 18% to EUR 77.2 million (previous year: EUR 65.2 million) in the financial year 2019. The consolidated net profit for the year increased by 47% to 9.7 million euros.
M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2019. In the past financial year, the M1 Group further strengthened its market leadership in Germany in the field of beauty medicine and accelerated its international expansion.
Following the federal and state governments announcement to continue the ban on contact to at least 19/20 April 2020, M1 Kliniken AG has decided to keep its own clinics and practices closed until 24 April 2020. Internally, however, plans for the reopening have already begun.
The M1 Group will close all clinic and practice locations for beauty treatments from 21.03.2020. Impact of corona pandemic on sales limited so far. Offers to health authorities to use the practice infrastructure as a corona or Covid19 test centres are planned.
M1 Kliniken AG (ISIN: DE000A0STSQ8) continued its growth course in the first half of 2019. In the first six months of the year, Germany’s market leader in the field of beauty medicine increased sales by 14% from EUR 28.9 million to EUR 32.9 million.
Today the Annual General Meeting 2019 of M1 Kliniken AG (ISIN: DE000A0STSQ8) took place in Berlin. The attendance was 77 %. The shareholders approved the proposal of the Management Board and Supervisory Board to distribute a dividend of 0.30 Euro per share for the financial year 2018.
After M1 Kliniken AG was able to increase the number of specialist centres to 24 by the end of the year in 2018, the group has created the prerequisites for further growth in Germany and abroad. The expansion of room capacities created the basis for a significantly larger number of doctors in aesthetic medicine.
M1 Kliniken AG today published its consolidated financial statements for 2018. The M1 Group further expanded its market leadership in Germany in the field of beauty medicine and expanded its range of services with “M1 Laser” and “M1 Dental” to include dermatological laser and aesthetic dental treatments.